See more : Magmatic Resources Limited (MAG.AX) Income Statement Analysis – Financial Results
Complete financial analysis of AstraZeneca PLC (ZEG.DE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AstraZeneca PLC, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Jinke Property Group Co., Ltd. (000656.SZ) Income Statement Analysis – Financial Results
- Discovery Silver Corp. (DSVSF) Income Statement Analysis – Financial Results
- Hektas Ticaret T.A.S. (HEKTS.IS) Income Statement Analysis – Financial Results
- gremz,Inc. (GRMZF) Income Statement Analysis – Financial Results
- Foley Wines Limited (FWL.NZ) Income Statement Analysis – Financial Results
AstraZeneca PLC (ZEG.DE)
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 45.81B | 44.35B | 37.42B | 26.62B | 24.38B | 22.09B | 22.47B | 23.00B | 24.71B | 26.10B | 25.71B | 27.97B | 33.59B | 33.27B | 32.80B | 31.60B | 29.56B | 26.48B | 23.95B | 21.43B | 18.85B | 17.85B | 23.57B | 18.12B | 18.44B | 9.15B | 8.59B | 9.18B | 7.57B | 7.00B | 6.57B | 6.03B | 7.35B | 7.35B |
Cost of Revenue | 8.04B | 12.39B | 12.44B | 5.30B | 4.92B | 4.94B | 4.32B | 4.13B | 4.65B | 5.84B | 5.26B | 5.39B | 6.03B | 6.39B | 5.78B | 6.60B | 6.00B | 5.56B | 5.36B | 5.19B | 4.47B | 4.52B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 37.77B | 31.96B | 24.98B | 21.32B | 19.46B | 17.15B | 18.15B | 18.88B | 20.06B | 20.25B | 20.45B | 22.58B | 27.57B | 26.88B | 27.03B | 25.00B | 23.56B | 20.92B | 18.59B | 16.23B | 14.38B | 13.33B | 23.57B | 18.12B | 18.44B | 9.15B | 8.59B | 9.18B | 7.57B | 7.00B | 6.57B | 6.03B | 7.35B | 7.35B |
Gross Profit Ratio | 82.45% | 72.06% | 66.76% | 80.09% | 79.82% | 77.66% | 80.78% | 82.06% | 81.20% | 77.61% | 79.54% | 80.72% | 82.06% | 80.80% | 82.40% | 79.12% | 79.69% | 79.00% | 77.64% | 75.76% | 76.29% | 74.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Research & Development | 11.02B | 9.76B | 9.74B | 5.99B | 5.96B | 5.93B | 5.76B | 5.89B | 6.00B | 5.58B | 4.82B | 5.24B | 5.52B | 5.32B | 4.41B | 4.95B | 5.09B | 3.90B | 3.38B | 3.47B | 3.45B | 3.07B | 3.97B | 2.89B | 2.92B | 1.18B | 1.08B | 1.03B | 848.32M | 809.84M | 767.71M | 676.44M | 703.57M | 704.06M |
General & Administrative | -197.00M | 0.00 | 0.00 | 0.00 | 11.68B | 0.00 | 10.23B | 9.41B | 11.11B | 13.00B | 12.21B | 9.84B | 11.16B | 10.45B | 11.33B | 11.20B | 10.61B | 9.32B | 8.91B | 8.27B | 6.86B | 6.00B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 18.22B | 18.96B | 15.68B | 11.69B | 11.85B | 10.36B | 10.54B | 9.74B | 11.45B | 13.32B | 12.51B | 10.16B | 11.51B | 335.00M | 298.00M | 10.64B | 10.13B | 9.32B | 8.91B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 18.03B | 18.96B | 15.68B | 11.69B | 11.85B | 10.36B | 10.54B | 9.74B | 11.45B | 13.32B | 12.51B | 10.16B | 11.51B | 10.78B | 11.63B | 10.64B | 10.13B | 9.32B | 8.91B | 8.27B | 6.86B | 6.00B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Expenses | 538.00M | -514.00M | -1.49B | -1.53B | -1.54B | -650.00M | -10.44B | -9.74B | -11.63B | -13.76B | -12.77B | -970.00M | 0.00 | 0.00 | -553.00M | -11.16B | -10.86B | -9.85B | -9.10B | -78.00M | -91.00M | -31.02M | 13.61B | 10.75B | 10.70B | 6.00B | 5.69B | 6.28B | 5.04B | 5.00B | 4.78B | 4.41B | 5.38B | 5.34B |
Operating Expenses | 29.58B | 28.20B | 23.92B | 16.16B | 16.27B | 13.77B | 14.47B | 13.97B | 15.95B | 18.12B | 16.74B | 14.43B | 16.25B | 15.39B | 15.49B | 15.45B | 14.50B | 12.70B | 12.09B | 11.69B | 10.27B | 8.97B | 17.58B | 13.64B | 13.62B | 7.17B | 6.77B | 7.32B | 5.89B | 5.81B | 5.55B | 5.09B | 6.08B | 6.04B |
Cost & Expenses | 37.62B | 40.59B | 36.36B | 21.46B | 21.19B | 18.70B | 18.79B | 18.10B | 20.59B | 23.96B | 22.00B | 19.83B | 22.28B | 21.78B | 21.26B | 22.05B | 20.50B | 18.26B | 17.45B | 16.88B | 14.74B | 13.49B | 17.58B | 13.64B | 13.62B | 7.17B | 6.77B | 7.32B | 5.89B | 5.81B | 5.55B | 5.09B | 6.08B | 6.04B |
Interest Income | 301.00M | 95.00M | 43.00M | 87.00M | 172.00M | 138.00M | 113.00M | 67.00M | 46.00M | 78.00M | 50.00M | 528.00M | 552.00M | 516.00M | 462.00M | 854.00M | 959.00M | 888.00M | 665.00M | 532.00M | 91.00M | 31.02M | 284.13M | 268.85M | 164.92M | 36.52M | 76.04M | 71.93M | 40.18M | 28.14M | 50.29M | 42.47M | 54.26M | 40.51M |
Interest Expense | 1.59B | 1.35B | 1.30B | 1.31B | 1.43B | 1.42B | 1.51B | 1.38B | 1.08B | 963.00M | 495.00M | 958.00M | 980.00M | 1.03B | 1.20B | 1.32B | 1.07B | 561.00M | 500.00M | 454.00M | 0.00 | 0.00 | 134.81M | 131.44M | 166.92M | 106.23M | 100.84M | 109.60M | 95.80M | 117.26M | 202.65M | 283.62M | 392.95M | 389.65M |
Depreciation & Amortization | 4.93B | 5.25B | 4.10B | 2.90B | 3.76B | 3.75B | 3.04B | 2.36B | 2.85B | 3.28B | 4.58B | 2.52B | 2.55B | 2.74B | 2.09B | 2.62B | 1.86B | 1.35B | 1.33B | 1.27B | 1.29B | 960.47M | 1.17B | 929.02M | 997.51M | 408.33M | 357.07M | 371.61M | 299.77M | 276.72M | 254.42M | 242.67M | 291.91M | 300.91M |
EBITDA | 13.42B | 9.09B | 5.11B | 8.08B | 6.71B | 7.11B | 6.62B | 7.28B | 6.96B | 5.49B | 8.34B | 10.68B | 15.39B | 14.74B | 13.95B | 12.62B | 9.95B | 9.56B | 7.83B | 5.82B | 5.30B | 4.97B | 5.02B | 4.91B | 4.50B | 3.25B | 2.24B | 2.15B | 1.35B | 1.48B | 1.37B | 687.06M | 1.68B | 1.37B |
EBITDA Ratio | 29.30% | 21.03% | 20.22% | 31.45% | 28.77% | 32.44% | 30.14% | 31.71% | 28.31% | 21.04% | 32.46% | 40.02% | 42.91% | 44.34% | 42.96% | 41.22% | 40.17% | 39.47% | 35.47% | 29.62% | 29.14% | 29.97% | 31.76% | 31.57% | 28.54% | 26.24% | 26.40% | 24.31% | 23.15% | 23.42% | 20.88% | 19.93% | 22.73% | 20.71% |
Operating Income | 8.19B | 3.76B | 1.06B | 5.16B | 2.92B | 3.39B | 3.68B | 4.90B | 4.11B | 2.14B | 3.71B | 8.15B | 12.80B | 11.49B | 11.54B | 9.14B | 8.09B | 8.22B | 6.50B | 4.55B | 4.11B | 4.36B | 5.66B | 3.67B | 2.67B | 1.82B | 1.79B | 1.79B | 1.28B | 1.03B | 1.04B | 429.22M | 1.28B | 1.16B |
Operating Income Ratio | 17.88% | 8.47% | 2.82% | 19.39% | 11.99% | 15.33% | 16.37% | 21.31% | 16.65% | 8.19% | 14.44% | 29.13% | 38.09% | 34.55% | 35.19% | 28.94% | 27.38% | 31.03% | 27.15% | 21.22% | 21.81% | 24.42% | 23.99% | 20.23% | 14.50% | 19.91% | 20.85% | 19.45% | 16.93% | 14.71% | 15.86% | 7.11% | 17.36% | 15.75% |
Total Other Income/Expenses | -1.29B | -1.26B | -1.32B | -1.25B | -1.38B | -1.39B | -1.45B | -1.35B | -1.05B | -891.00M | -445.00M | -502.00M | -512.00M | -517.00M | -736.00M | -463.00M | -111.00M | 327.00M | 165.00M | 297.00M | 70.00M | 4.85M | 102.00M | 185.21M | 126.00M | 697.00M | -3.31M | -116.45M | -324.49M | 0.00 | -105.02M | -274.52M | -282.55M | -474.52M |
Income Before Tax | 6.90B | 2.50B | -265.00M | 3.92B | 1.55B | 1.99B | 2.23B | 3.55B | 3.07B | 1.25B | 3.27B | 7.72B | 12.37B | 10.98B | 10.81B | 8.68B | 7.98B | 8.54B | 6.67B | 4.84B | 4.20B | 4.04B | 5.83B | 3.85B | 1.96B | 1.73B | 1.79B | 1.67B | 956.49M | 1.03B | 936.34M | 154.70M | 993.60M | 682.84M |
Income Before Tax Ratio | 15.06% | 5.64% | -0.71% | 14.71% | 6.35% | 9.02% | 9.91% | 15.44% | 12.42% | 4.77% | 12.71% | 27.59% | 36.82% | 32.99% | 32.94% | 27.47% | 27.01% | 32.27% | 27.84% | 22.61% | 22.29% | 22.63% | 24.74% | 21.25% | 10.62% | 18.97% | 20.81% | 18.18% | 12.64% | 14.71% | 14.26% | 2.56% | 13.51% | 9.29% |
Income Tax Expense | 938.00M | -792.00M | -380.00M | 772.00M | 321.00M | -57.00M | -641.00M | 146.00M | 243.00M | 11.00M | 696.00M | 1.39B | 2.35B | 2.90B | 3.26B | 2.55B | 2.36B | 2.48B | 1.94B | 1.16B | 1.14B | 1.18B | 1.66B | 1.30B | 814.60M | 547.76M | 570.32M | 548.00M | 414.12M | 328.31M | 279.57M | 15.17M | 312.49M | 231.47M |
Net Income | 5.96B | 3.29B | 112.00M | 3.20B | 1.34B | 2.16B | 3.00B | 3.50B | 2.83B | 1.23B | 2.56B | 6.30B | 9.98B | 8.05B | 7.52B | 6.10B | 5.60B | 6.04B | 4.71B | 3.66B | 3.04B | 2.84B | 4.16B | 2.54B | 1.14B | 1.19B | 1.21B | 1.10B | 519.19M | 692.59M | 637.54M | 121.34M | 645.56M | 428.22M |
Net Income Ratio | 13.00% | 7.41% | 0.30% | 12.01% | 5.47% | 9.76% | 13.36% | 15.21% | 11.43% | 4.73% | 9.94% | 22.51% | 29.72% | 24.21% | 22.93% | 19.31% | 18.93% | 22.83% | 19.65% | 17.10% | 16.11% | 15.90% | 17.63% | 14.02% | 6.20% | 12.96% | 14.05% | 11.99% | 6.86% | 9.89% | 9.71% | 2.01% | 8.78% | 5.83% |
EPS | 3.81 | 2.12 | 0.08 | 2.44 | 1.03 | 1.70 | 2.37 | 2.77 | 2.23 | 0.98 | 2.04 | 4.99 | 7.33 | 5.60 | 5.19 | 4.20 | 3.74 | 3.86 | 2.91 | 218.00 | 178.00 | 1.64 | 1.65 | 1.43 | 0.64 | 1.47 | 1.27 | 1.16 | 0.55 | 0.73 | 0.75 | 0.17 | 0.90 | 0.60 |
EPS Diluted | 3.81 | 2.11 | 0.08 | 2.44 | 1.03 | 1.70 | 2.37 | 2.76 | 2.23 | 0.98 | 2.04 | 4.93 | 7.30 | 5.57 | 5.19 | 4.20 | 3.73 | 3.85 | 2.91 | 218.00 | 178.00 | 1.64 | 1.65 | 1.43 | 0.64 | 1.46 | 1.27 | 1.16 | 0.55 | 0.73 | 0.75 | 0.17 | 0.90 | 0.60 |
Weighted Avg Shares Out | 1.56B | 1.55B | 1.42B | 1.31B | 1.30B | 1.27B | 1.27B | 1.27B | 1.26B | 1.26B | 1.25B | 1.26B | 1.36B | 1.44B | 1.45B | 1.45B | 1.50B | 1.56B | 1.62B | 1.67B | 1.71B | 1.73B | 1.76B | 1.77B | 1.78B | 1.78B | 948.00M | 947.00M | 946.00M | 946.00M | 850.00M | 716.59M | 716.59M | 716.59M |
Weighted Avg Shares Out (Dil) | 1.56B | 1.56B | 1.43B | 1.31B | 1.30B | 1.27B | 1.27B | 1.27B | 1.27B | 1.26B | 1.25B | 1.26B | 1.37B | 1.45B | 1.45B | 1.45B | 1.50B | 1.57B | 1.62B | 1.67B | 1.71B | 1.74B | 1.76B | 1.77B | 1.78B | 1.78B | 951.00M | 947.00M | 946.00M | 946.00M | 850.00M | 716.59M | 716.59M | 716.59M |
Source: https://incomestatements.info
Category: Stock Reports
What was the impact of COVID-19 medicines on AstraZeneca’s revenue?
The company noted that revenue was negatively affected by slumping sales of COVID-19 vaccines and immune therapies (V&I), which reduced the total by $3.74 billion.
How did AstraZeneca’s product sales grow in Q1 2024?
The company’s total revenue surged by 19% to $12.68bn in Q1 2024, up from $10.88bn in the previous year’s same quarter. The rise in revenue was driven by an 18% increase in product sales and sustained growth in alliance revenue from partnered medicines.
How did AstraZeneca’s core EPS change in Q1 2024?
Rare disease revenue advanced 16%. Core operating margin clocked in at 34%, whereas the core earnings per share rose 13%, coming in at $2.06. Core Product Sales gross margin was 82% for the first quarter of the year.
What was AstraZeneca’s total revenue in Q1 2024?
The company’s total revenue surged by 19% to $12.68bn in Q1 2024, up from $10.88bn in the previous year’s same quarter.